Jointly provided by the University of Cincinnati and RedMedEd
Support for this activity has been provided through an educational grant from Pfizer.
Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way.
In the format of an entertaining (but challenging!) interactive game, this edition of Scale, Bail or Fail presents and discusses the latest updates on CDK4/6 inhibition research and its clinical implications. This activity also features downloadable resources (including supplemental figures and tables).
This activity has been designed to meet the educational needs of medical oncologists, laboratory scientists and clinical investigators specializing in all aspects of cancer research, and other health care professionals interested in understanding the research advances in CDK4/6 inhibition.
Upon completion of this activity, participants should be able to:
Explain the mechanism of action of CDK4/6 inhibitors
Evaluate safety and efficacy data on the use of CDK4/6 inhibitors for solid tumors and their potential implications for clinical practice
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
Richard S. Finn, MD—Program Chair Associate Professor of Medicine University of California, Los Angeles Los Angeles, CA
Dr. Finn has disclosed the following relevant financial relationships: Consultant: Bayer, Bristol-Myers Squibb, Novartis, Pfizer
Gary K. Schwartz, MD Professor of Medicine Chief, Division of Hematology and Oncology Deputy Chief, Herbert Irving Comprehensive Cancer Center Columbia University Medical Center New York, NY
Dr. Schwartz has disclosed the following relevant financial relationships: Advisory Board: Bionaut Labs, Champions Oncology, Human Longevity, Karyopharm Consultant: BioMotiv, Darwin Health, Puretech Health Other Relationships: AXIS Medical Education, Medscape/WedMD
Geoffrey I. Shapiro, MD, PhD Director, Early Drug Development Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, MA
Dr. Shapiro has disclosed the following relevant financial relationships: Advisory Board: G1 Therapeutics, Lilly, Pfizer, Vertex Grant Recipient: Pfizer
Accredited Provider Disclosures
University of Cincinnati Deborah Cole, Program Coordinator, has disclosed no relevant financial relationships. Rick E. Ricer, MD, Professor Emeritus, UC Physician Reviewer, has disclosed no relevant financial relationships. Susan P. Tyler, MEd, CMP, CHCP, CME Director, has disclosed no relevant financial relationships.
RedMedEd Denise C. LaTemple, PhD, Director of Scientific Services, has disclosed no relevant financial relationships. Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships. Karen Smith, Creative Director, has disclosed no relevant financial relationships. Karen Tenaglia, Project Manager, has disclosed no relevant financial relationships. Barbara Zosh, Director of Operations, has disclosed on relevant financial relationships.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati, RedMedEd, and Pfizer do not recommend the use of any agent outside the labeled indications.
Dr. Finn will discuss the off-label use of abemaciclib, palbociclib, and ribociclib.
Dr. Shapiro will discuss the off-label use of abemaciclib, G1T28, palbociclib, and ribociclib.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati, RedMedEd, or Pfizer. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Clicking "START ACTIVITY" will send you away from myCME to our partner site, RedMedEd.
There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the entire activity (achieving a passing grade by correctly answering at least nine questions) and program evaluation. Certificates can be printed immediately and will not be stored in your myCME CME History.
For questions regarding CME credit, please contact the University of Cincinnati Continuing Medical Education Department at firstname.lastname@example.org or call (513) 558-7277.
For technical questions related to this activity, please contact RedMedEd at (610) 251-6841 or email@example.com.
Apple iPad or iPad mini (iOS 8 or higher) with an Internet connection
A computer with an Internet connection
Internet browser: Google Chrome, Internet Explorer 9 or higher, Firefox 26 or higher, or Safari 5 or higher
Additional software: Adobe Flash Player and/or an HTML 5-capable browser is required for video or audio playback; Adobe Acrobat Reader may occasionally be required